BioHarvest Sciences Inc. (BHST)

Nasdaq: BHST · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2017

Full chart Alerts Compare

Grade6.1

◀ Past 7.0● Present 5.6▶ Future 5.9

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of BioHarvest Sciences Inc.

Nine metrics read from its own filings, by tense

Headline grade

6.1/10

◀ Past7.025% of the headline

● Present5.635% of the headline

▶ Future5.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.0/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

BioHarvest Sciences Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.3/10

What has it actually done, year after year?

+65% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 73rd percentile among 323 sector filers · read for its customers

From the record

BioHarvest Sciences Inc.'s 3 filed years say what it did: revenue went from $13 million in fiscal 2023 to $35 million in fiscal 2025, up 65% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span65.0%top 18% of its family
the share of years revenue rosetop 8% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.8/10

How has it treated the people who own it?

SI estimate 5.8/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 295 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: family median, 295 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioHarvest Sciences Inc.'s shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.6/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

5.6/10

Is it financially healthy right now?

ROE -44%: lost 44¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar.

weight 45% of this tense · 56th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioHarvest Sciences Inc. lost about 44 cents for every dollar of shareholders' money, and gross profitability: its products earned about 43 cents per dollar of everything the company owns. Leverage: it owed about 47 cents per dollar of assets (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 37% of its family
return on equitytop 45% of its family
gross profit against assetstop 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

6.5/10

How strong is its position in its industry?

top 35% of 315 in its family; net margin -32.3%.

weight 22% of this tense · 65th percentile among 315 sector filers · read for its customers

From the record

BioHarvest Sciences Inc.'s standing among 315 graded names in its industry family: revenue of $35 million in fiscal 2025 ranks in the top 49% by size; a net margin of -32.3% ranks in the top 37%; revenue growth of 65% a year over the last 2 filed years ranks in the top 19% (its annual reports).

What it rests on

revenue against the family$34.5Mtop 49% of its family
net margin-32.3%top 37% of its family
three-year revenue growth65.0%top 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioHarvest Sciences Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.9/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

4.6/10

How much room does it have to grow?

bottom 46% of 273 in its family for room to expand.

weight 33% of this tense · 46th percentile among 273 sector filers · read for itself

From the record

BioHarvest Sciences Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $23 million against no long-term debt tagged leaves 48.3% of its assets as net cash, top 34% of its family; cash from operations less capital spending is -27.8% of revenue (top 40%); a gross margin of 59.3% (bottom 36%); research spending of 15.4% of revenue (bottom 19%) (its annual report).

What it rests on

cash less debt against assets48.3%top 34% of its family
cash from operations less capital spending against revenue-27.8%top 40% of its family
gross margin59.3%bottom 36% of its family
research spending against revenue15.4%bottom 19% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.3/10

What could actually drive growth from here?

top 27% of 306 in its family for growth drivers.

weight 45% of this tense · 73rd percentile among 306 sector filers · read for its customers

From the record

BioHarvest Sciences Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 65% a year over the last three filed years against 65% over all 3, speeding up (top 40% of its family); the newest year grew 37% (top 30%); research spending grew 25.5% a year (top 18%); capital spending grew 26.4% a year (top 22%) (its annual reports). BioHarvest Sciences Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
the newest year's revenue growth37.0%top 30% of its family
three-year growth of research spending25.5%top 18% of its family
three-year growth of capital spending26.4%top 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioHarvest Sciences Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BHST · research, not advice